Protagonist Therapeutics Announces Abstracts Selected For Oral And Poster Presentations At The American Society Of Hematology 2023 Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) has announced that five abstracts related to its rusfertide program have been accepted for presentation at the 65th American Society of Hematology Annual Meeting and Exposition. The presentations will cover new data on rusfertide's potential therapeutic value in the treatment of Polycythemia Vera and other diseases, as well as epidemiological aspects of PV and preclinical data on a hepcidin mimetic treatment in a mouse model for sickle cell disease.
November 02, 2023 | 1:23 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Protagonist Therapeutics' announcement of the acceptance of five abstracts related to its rusfertide program for presentation at a major hematology meeting could potentially boost investor confidence in the company's research and development capabilities.
The acceptance of the abstracts for presentation at a major conference indicates recognition from the scientific community, which could positively impact the company's reputation and investor confidence. However, the actual impact on the stock price will depend on the reception of the presentations and the data revealed.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100